CRISPR Therapeutics AG (CRSP) financial statements (2020 and earlier)

Company profile

Business Address BAARERSTRASSE 14
ZUG, CH-6300
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments944457240316
Cash and cash equivalents944457240316
Receivables0034
Other undisclosed current assets441051
Total current assets:988466248320
Noncurrent Assets
Operating lease, right-of-use asset42
Property, plant and equipment31191921
Intangible assets, net (including goodwill)0000
Intangible assets, net (excluding goodwill)0000
Restricted cash and investments5333
Other noncurrent assets1110
Total noncurrent assets:79232325
TOTAL ASSETS:1,067489271345
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37261321
Accounts payable6525
Accrued liabilities30211116
Taxes payable1000
Deferred revenue1
Debt8   
Deferred rent credit 1
Deferred revenue and credits11
Other liabilities11000
Total current liabilities:57281522
Noncurrent Liabilities
Long-term debt and lease obligation44   
Operating lease, liability44
Liabilities, other than long-term debt26696990
Deferred revenue and credits6990
Deferred revenue12
Contract with customer, liability58
Deferred rent credit 11
Other liabilities14000
Total noncurrent liabilities:70696990
Total liabilities:1279784112
Stockholders' equity
Stockholders' equity attributable to parent939392188233
Common stock2211
Treasury stock, value(0)(0)  
Additional paid in capital1,162682312289
Accumulated other comprehensive income (loss)0(0)0(0)
Accumulated deficit(225)(292)(125)(57)
Total stockholders' equity:939392188233
TOTAL LIABILITIES AND EQUITY:1,067489271345

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net51
Revenue from related parties13
Gross profit:2903415
Operating expenses(243)(162)(106)(73)
Operating income (loss):47(159)(65)(68)
Nonoperating income (expense)21(5)(2)45
Other nonoperating income (expense)26(1)(0)79
Interest and debt expense   11
Income (loss) from continuing operations before equity method investments, income taxes:67(164)(67)(11)
Loss from equity method investments(5)(4)(2)(37)
Other undisclosed income from continuing operations before income taxes54225
Income (loss) from continuing operations before income taxes:67(164)(67)(23)
Income tax expense(0)(1)(2)(0)
Net income (loss):67(165)(68)(23)
Net income attributable to noncontrolling interest   0
Net income (loss) available to common stockholders, diluted:67(165)(68)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):67(165)(68)(23)
Other comprehensive income (loss) (0)0 
Comprehensive income (loss):67(165)(68)(23)
Comprehensive income, net of tax, attributable to noncontrolling interest   0
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0  (0)
Comprehensive income (loss), net of tax, attributable to parent:67(165)(68)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: